gastric cancer
Conditions
Interventions
Gold Standard:Gastroscope+histopathology
Index test:GeneCast MethylSeq platform,Methylated Fragment Ratio(MFR),Chromosomal aneuploidy of featured fragments(CAFF),Fragment Size Index (FSI),Fragment End Motif(FEM).
Sponsors
The First Affiliated Hospital of Air Force Military Medical University (Xijing Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Gastric cancer group: patients with gastric cancer confirmed by pathology; 2. Noncancer group: normal people or subjects with non-atrophic gastritis, gastric ulcer, gastric polyp, and other benign diseases confirmed by gastroscopy and/or histopathology; 3. Complete clinical data; 4. Subjects voluntarily participated in the study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Previous history of malignant tumor; 2. Patients with two or more malignant tumors at the same time; 3. The primary lesion could not be confirmed by pathological evaluation; 4. Previous history of total or partial gastrectomy; 5. Previous bone marrow or organ transplantation; 6. Those who had a history of blood transfusion 6 months before enrollment; 7. Subjects who received anti-tumor treatment before blood draw; 8. Those who refused to sign the informed consent form to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Genome wide methylation detection; | — |
Countries
China
Contacts
Public ContactJi Gang
Xijing Hospital of Air Force Military Medical University
Outcome results
None listed